Uganda’s 2026 Ebola Outbreak: How a Cross-Border Spillover Was Contained

Of Uganda's 20 confirmed cases, 15 were imported from the DRC and five were locally acquired through secondary transmission . Two Congolese nationals died, and one additional probable case also died . The last patient was discharged from a treatment center on July 16, 2026, triggering the 42-day countdown . No new cases were reported in Uganda after June 21, 2026 .

The DRC Epidemic: Rapidly Worsening

The DRC's Bundibugyo virus outbreak, first reported on May 14, 2026, in Ituri Province, has become one of the largest and fastest-growing Ebola outbreaks on record . The WHO Director-General warned on July 16, 2026, that the outbreak is "outpacing response" efforts despite major mobilization . By comparison, the 2018–2019 Ebola outbreak in the DRC took more than 10 months to reach 2,000 confirmed cases; this outbreak did so in roughly two months .

Key case numbers from official sources:

• As of early July 2026 (WHO/ECDC): 1,759 confirmed cases and 600 confirmed deaths .
• By July 13, 2026 (UK government monitoring): 2,011 confirmed cases and 754 confirmed deaths .
• By July 16, 2026 (Al Jazeera): Over 2,073 confirmed infections and 796 deaths, with the WHO warning the true tally could be at least double that .

Beyond the DRC and Uganda, imported cases appeared in Europe: one case in France involved a physician returning from the DRC who fully recovered without secondary transmission, and a case was reported in Germany .

Border Closure and International Travel Restrictions

Uganda closed its border with the DRC on May 27, 2026, a temporary measure that permitted crossings only for outbreak response, humanitarian operations, essential cargo, and authorized travelers . All authorized entrants were subjected to strict health screening and monitoring .

The U.S. Centers for Disease Control and Prevention (CDC) issued a Level 4 "Do Not Travel" advisory for Uganda and the DRC on May 27, 2026, and restricted non-essential travel . The U.S. State Department matched the CDC with a Level 4 advisory . Canada also imposed travel restrictions on Uganda and the DRC due to the outbreak.

No Approved Vaccine or Treatment for Bundibugyo

A critical factor in the outbreak's severity is the absence of any licensed vaccine or treatment specifically for the Bundibugyo virus species . Merck's Ervebo vaccine is licensed only for Zaire ebolavirus, not Bundibugyo . A specific Bundibugyo vaccine candidate (rVΔ/BDB-GP), using the same platform as Ervebo, showed survival benefits in non-human primates but has not been licensed . Animal model data suggest Ervebo may provide partial cross-protection against Bundibugyo, but no clinical evidence existed as of early July . The WHO has recommended that Ervebo should not be used outside carefully designed research settings .

Africa CDC Prepares Ervebo Cross-Protection Trial

In response, the Africa CDC and partners began organizing clinical trials in the DRC to test whether Merck's Ervebo vaccine can provide cross-protection against the Bundibugyo strain . A July 2026 human serology study published in the New England Journal of Medicine found that Ervebo may offer partial protection, supporting the rationale for the trial . The trials aim to protect frontline health workers in the DRC . However, the African Medicines Agency (AMA) has stated that existing countermeasures are "unlikely to provide adequate protection without adaptation," highlighting the uncertainty .

Broader Regional Challenges

The response faces severe systemic obstacles:

• Attacks on health facilities: Health workers and treatment centers have been targeted amid the armed conflict in eastern DRC .
• Armed conflict: The outbreak zone overlaps with active conflict zones (Ituri, North Kivu, South Kivu), hampering response access .
• Community mistrust: Historical distrust of health authorities in the region has complicated contact tracing and safe burial practices .

The end result is a regional picture with two starkly different narratives. Uganda successfully contained its cross-border spillover through rapid border controls, surveillance, and treatment of all confirmed cases. Meanwhile, the DRC epidemic continues to accelerate with no licensed medical countermeasures and severe operational challenges.